$EVOK
Evoke Pharma Inc

2020 Q2 Form 10-Q Financial Statement

#000156459020037301 Filed on August 06, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.180M $920.0K
YoY Change 28.26% 0.0%
% of Gross Profit
Research & Development $5.782M $1.206M
YoY Change 379.6% -13.19%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $6.965M $2.124M
YoY Change 227.96% -7.91%
Operating Profit -$6.965M -$2.124M
YoY Change 227.96% -7.91%
Interest Expense $2.914K $9.642K
YoY Change -69.78% 232.14%
% of Operating Profit
Other Income/Expense, Net -$2.429K $9.642K
YoY Change -125.19% 232.25%
Pretax Income -$6.970M -$2.110M
YoY Change 230.33% -8.26%
Income Tax
% Of Pretax Income
Net Earnings -$6.967M -$2.114M
YoY Change 229.57% -8.21%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$278.9K -$90.71K
COMMON SHARES
Basic Shares Outstanding 23.26M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q2 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $7.990M $7.440M
YoY Change 7.39% 13.94%
Cash & Equivalents $7.990M $7.440M
Short-Term Investments
Other Short-Term Assets $200.0K $11.55K
YoY Change 1631.45% -87.17%
Inventory
Prepaid Expenses $109.7K
Receivables
Other Receivables
Total Short-Term Assets $8.200M $7.561M
YoY Change 8.45% 14.05%
LONG-TERM ASSETS
Property, Plant & Equipment $70.00K $70.00K
YoY Change 0.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $0.00
YoY Change
Total Long-Term Assets $70.00K $69.80K
YoY Change 0.29%
TOTAL ASSETS
Total Short-Term Assets $8.200M $7.561M
Total Long-Term Assets $70.00K $69.80K
Total Assets $8.270M $7.631M
YoY Change 8.37% 15.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $600.0K $410.0K
YoY Change 46.34% -6.82%
Accrued Expenses $930.0K $880.0K
YoY Change 5.68% 7.32%
Deferred Revenue
YoY Change
Short-Term Debt $100.0K $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.640M $1.285M
YoY Change 416.72% 1.18%
LONG-TERM LIABILITIES
Long-Term Debt $2.000M $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $2.000M $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $6.640M $1.285M
Total Long-Term Liabilities $2.000M $0.00
Total Liabilities $8.641M $1.290M
YoY Change 569.82% 1.57%
SHAREHOLDERS EQUITY
Retained Earnings -$94.49M
YoY Change
Common Stock $94.11M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$373.7K $6.346M
YoY Change
Total Liabilities & Shareholders Equity $8.267M $7.630M
YoY Change 8.35% 15.08%

Cashflow Statement

Concept 2020 Q2 2019 Q2
OPERATING ACTIVITIES
Net Income -$6.967M -$2.114M
YoY Change 229.57% -8.21%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$1.560M -$1.630M
YoY Change -4.29% -7.39%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.410M 5.040M
YoY Change 7.34% 74.39%
NET CHANGE
Cash From Operating Activities -1.560M -1.630M
Cash From Investing Activities
Cash From Financing Activities 5.410M 5.040M
Net Change In Cash 3.850M 3.410M
YoY Change 12.9% 201.77%
FREE CASH FLOW
Cash From Operating Activities -$1.560M -$1.630M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.35
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24987975
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23258567
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q2 evok Paycheck Protection Program Loan
PaycheckProtectionProgramLoan
104168
CY2020Q2 evok Milestone Payable
MilestonePayable
5000000
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q2 us-gaap Liabilities
Liabilities
8640732
CY2019Q4 us-gaap Liabilities
Liabilities
2015083
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
2601
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
2443
CY2020Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
94111817
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-94488094
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-373676
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8267056
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26011263
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24431914
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26011263
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24431914
CY2020Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
5782094
CY2019Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
1205599
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
6245946
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1182872
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
918139
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2512707
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
6964966
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
2123738
us-gaap Operating Expenses
OperatingExpenses
8758653
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6964966
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2123738
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.28
us-gaap Net Income Loss
NetIncomeLoss
-8757704
us-gaap Net Income Loss
NetIncomeLoss
-4079362
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.09
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
14271
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
1952481
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2141152
us-gaap Operating Expenses
OperatingExpenses
4093633
us-gaap Operating Income Loss
OperatingIncomeLoss
-4093633
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20371442
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
14271
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.20
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
378959
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6395628
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
90108492
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-85730390
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
4380545
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
4025320
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-1965266
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
3075445
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
344841
CY2019Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5039956
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
3863
us-gaap Operating Income Loss
OperatingIncomeLoss
-8758653
CY2020Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
485
CY2019Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
9642
CY2020Q2 us-gaap Interest Expense
InterestExpense
2914
us-gaap Interest Expense
InterestExpense
2914
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2429
CY2019Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
9642
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
949
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-6967395
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-2114096
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24713928
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
310162
CY2020Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
21250
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
2921648
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
362955
CY2019Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
636432
us-gaap Share Based Compensation
ShareBasedCompensation
673117
us-gaap Share Based Compensation
ShareBasedCompensation
723800
evok Milestone Expense
MilestoneExpense
5000000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-455131
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-285496
evok Increase Decrease In Accounts Payable And Other Current Liabilities
IncreaseDecreaseInAccountsPayableAndOtherCurrentLiabilities
-478519
evok Increase Decrease In Accounts Payable And Other Current Liabilities
IncreaseDecreaseInAccountsPayableAndOtherCurrentLiabilities
-485247
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3107975
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3555313
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3330366
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5676388
us-gaap Proceeds From Issuance Of Unsecured Debt
ProceedsFromIssuanceOfUnsecuredDebt
104168
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
2000000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5434534
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5676388
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2326559
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2121075
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5319004
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7440079
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ materially from those estimates. </p>
evok Entity Incorporation Month And Year Of Incorporation
EntityIncorporationMonthAndYearOfIncorporation
2007-01
CY2020Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6666927
CY2019Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5946432
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6691641
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5946432
CY2007Q2 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
650000
CY2020Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
393084
evok Issuance Of Common Stock From Warrant Exercise Shares
IssuanceOfCommonStockFromWarrantExerciseShares
158494
CY2020Q2 us-gaap Share Based Compensation
ShareBasedCompensation
362955
CY2019Q2 us-gaap Share Based Compensation
ShareBasedCompensation
344841
CY2020Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2900000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y2M8D

Files In Submission

Name View Source Status
0001564590-20-037301-index-headers.html Edgar Link pending
0001564590-20-037301-index.html Edgar Link pending
0001564590-20-037301.txt Edgar Link pending
0001564590-20-037301-xbrl.zip Edgar Link pending
evok-10q_20200630.htm Edgar Link pending
evok-20200630.xml Edgar Link completed
evok-20200630.xsd Edgar Link pending
evok-20200630_cal.xml Edgar Link unprocessable
evok-20200630_def.xml Edgar Link unprocessable
evok-20200630_lab.xml Edgar Link unprocessable
evok-20200630_pre.xml Edgar Link unprocessable
evok-ex311_6.htm Edgar Link pending
evok-ex312_10.htm Edgar Link pending
evok-ex321_12.htm Edgar Link pending
evok-ex322_9.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending